Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P14678
UPID:
RSMB_HUMAN
Alternative names:
Sm protein B/B'
Alternative UPACC:
P14678; Q15490; Q6IB35; Q9UIS5
Background:
Small nuclear ribonucleoprotein-associated proteins B and B', also known as Sm protein B/B', play a crucial role in pre-mRNA splicing. They are core components of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), essential for the spliceosome's assembly and function. These proteins are involved in the splicing of U12-type introns and in histone pre-mRNA 3'-end processing, highlighting their importance in RNA metabolism.
Therapeutic significance:
The association of Small nuclear ribonucleoprotein-associated proteins B and B' with Cerebrocostomandibular syndrome, a condition marked by severe micrognathia, rib defects, and intellectual disability, underscores their potential as targets for therapeutic intervention. Understanding the role of these proteins could open doors to potential therapeutic strategies.